 Lymphoma, B-Cell
"Lymphoma, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Descriptor ID |
D016393
|
| MeSH Number(s) |
C04.557.386.480.150 C15.604.515.569.480.150 C20.683.515.761.480.150
|
| Concept/Terms |
Lymphoma, B-Cell- Lymphoma, B-Cell
- Lymphoma, B Cell
- B-Cell Lymphoma
- B Cell Lymphoma
- B-Cell Lymphomas
- Lymphomas, B-Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell".
This graph shows the total number of publications written about "Lymphoma, B-Cell" by people in this website by year, and whether "Lymphoma, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 2 | 0 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 0 | 1 | 1 | | 2004 | 2 | 0 | 2 | | 2005 | 1 | 1 | 2 | | 2006 | 4 | 0 | 4 | | 2007 | 1 | 1 | 2 | | 2009 | 3 | 0 | 3 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 1 | 2 | | 2012 | 3 | 0 | 3 | | 2013 | 6 | 1 | 7 | | 2014 | 3 | 1 | 4 | | 2015 | 2 | 0 | 2 | | 2016 | 2 | 0 | 2 | | 2017 | 4 | 1 | 5 | | 2018 | 4 | 1 | 5 | | 2019 | 4 | 0 | 4 | | 2020 | 7 | 0 | 7 | | 2021 | 4 | 0 | 4 | | 2022 | 13 | 0 | 13 | | 2023 | 8 | 0 | 8 | | 2024 | 3 | 2 | 5 | | 2025 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, B-Cell" by people in Profiles.
-
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Saito NG, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025. J Natl Compr Canc Netw. 2025 Oct; 23(10).
-
Porche K, King RL, Habermann TM, Johnston PB, Spinner RJ. Low-Grade B-Cell Neurolymphomatosis: A Case Series and Diagnostic Insight. World Neurosurg. 2025 Sep; 201:124260.
-
Strati P, Castro J, Goodman A, Bachanova V, Kamdar M, Awan FT, Solomon SR, Wong L, Wong C, Patel D, Bickers C, Zhao W, Bashir Z, Valamehr B, Elstrom RL, Patel K. Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study. Lancet Haematol. 2025 Jul; 12(7):e505-e515.
-
Jain H, Karulkar A, Kalra D, Ravikumar S, Shah S, Firfiray A, Pendhari J, Jaiswal AK, Khan A, Sundharam M, Vaibhaw A, Saroha A, Rajyopadhye S, Basu M, Asija S, Chowdhury A, Beher R, Banik A, Dwivedi A, Purwar S, Narula G, Banavali S, Jain N, Highfill SL, Stroncek D, Fry T, Melinkeri S, Wilson L, Agarwal N, Aribandi A, Boyella PK, Shah NN, Neelapu SS, Sengar M, Purwar R. Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study. Lancet Haematol. 2025 Apr; 12(4):e282-e293.
-
Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez JC. Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone Marrow Transplant. 2025 May; 60(5):632-639.
-
Kent A, Yee Mon KJ, Hutchins Z, Putzel G, Zhigarev D, Grier A, Jia B, Kortlever RM, Barbet G, Evan GI, Blander JM. A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis. Nat Immunol. 2025 Jan; 26(1):53-67.
-
Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein P, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Adv. 2024 10 22; 8(20):5355-5364.
-
Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, Wang Y, Iqbal M, Alhaj Moustafa M, Murthy HS, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy. Blood Adv. 2024 09 24; 8(18):4877-4885.
-
Colton M, Purev E, Haverkos B, Bair S, Jasem J, Jacob A, Kamdar M. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):778-782.
-
Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. Targeting TGFß-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer. 2024 Aug; 5(8):1227-1249.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|